Novo Nordisk To Provide Refunds on Ozempic and Three Other Drugs to 340B Entities

Drugmaker Novo Nordisk is providing refunds to 340B covered entities on its blockbuster diabetes/weight loss drug Ozempic and three other products.
Drugmaker Novo Nordisk announced it is providing 340B covered entities 12-months-worth of refunds on four drug products including two of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Drugs Reach 18% of Outpatient Drug Sales, Says PhRMA-Backed Research; Providers Say It is Misleading

A PhRMA funded report found that 340B drugs grew to 18% of total outpatient branded drug sales in 2022. The figures were criticized by 340B providers and others as misleading.
340B drugs have steadily increased as a share of U.S. branded outpatient pharmaceutical sales and reached 18% of the total [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Hospitals Should Consider Internal Pharmacies, Selective Contracting, Says Consulting Group

Executives at a healthcare financial consulting group recommended 340B hospitals consider using in-house pharmacies.
Hospitals in the 340B program should respond to increasing drugmaker contract pharmacy restrictions by opening their own pharmacies or selectively [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Virginia Governor Vetoes 340B Contract Pharmacy Access Law that Nearly Unanimously Passed State Legislature

Virginia Gov. Glenn Youngkin (R) vetoed 340B contract pharmacy access legislation after the state senate rejected his proposed amendment.
Virginia Gov. Glenn Youngkin (R) late Friday vetoed a bill that would have prohibited drugmaker contract pharmacy restrictions on grantee [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

On Final Day of Session, Missouri House Passes 340B Contract Pharmacy Access Bill, Sends to Governor’s Desk

Missouri House 340B
The Missouri House overwhelmingly passed a 340B contract pharmacy access bill on the final day of the state's legislative session.
On the final day of Missouri’s legislative session, lawmakers overwhelmingly passed a bill to bar drugmaker 340B contract pharmacy restrictions [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Breaking News

Kansas Governor Rejects Provision to Delay New 340B Contract Pharmacy Protections

Kansas Gov. Laura Kelly (D) vetoed provisions of a bill that would have delayed a 340B contract pharmacy access law from taking effect.
A Kansas law that prohibits drugmaker 340B contract pharmacy restrictions is set to take effect July 1, as result of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Maryland Is Sixth State to Enact 340B Contract Pharmacy Access Law

Maryland Gov. Wes Moore (right) will make Maryland the sixth state to prohibit drugmaker 340B contract pharmacy restrictions when he signs legislation today.
Maryland Gov. Wes Moore (D) this morning is signing legislation to make Maryland the sixth state to prohibit drugmaker 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CVS Cites 340B Contract Pharmacy Restrictions in 19% Income Drop in Its Pharmacy Services

CVS Health said drugmaker 340B contract pharmacy restrictions contributed to a decline in the company's pharmacy services revenue.
CVS Health recently cited drug manufacturers’ contract pharmacy restrictions as one of the causes for a 19% year-over-year income decline [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Federal Court Sets April 2025 Trial for AstraZeneca’s Arkansas 340B Law Challenge Amid State Enforcement Actions

The trial for drugmaker AstraZeneca's lawsuit against Arkansas' 340B contract pharmacy access law will take place in April 2025.
A federal judge scheduled an April 2025 trial date for AstraZeneca’s lawsuit against Arkansas’ 340B contract pharmacy access law as [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Sales Increased 17% to $124B in 2023, Drug Industry Consulting Firm Finds 

Analysts from IQVIA found that 340B wholesale acquisition cost sales increased by 17% from 2022 to 2023.
The 340B program continued to expand in 2023, exceeding $124 billion in wholesale acquisition cost (WAC) sales—up from $107 billion [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live